Onychomycosis

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis

Retrieved on: 
Wednesday, January 31, 2024
Streptomyces, Fungal infection, Investigational New Drug, Venous stasis, Nail disease, Prevalence, IND, HDAC, Dermatophytosis, FDA, Ciclopirox, Onycholysis, Food, Vanda, Onychomycosis, Fungus, Antibiotics

WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.

Key Points: 
  • WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.
  • Onychomycosis, or tinea unguium, is a fungal infection of the nail.
  • Onychomycosis can result in discoloration of the nail, onycholysis (nail separation from the nail bed), and nail plate thickening.
  • There have not been any new onychomycosis treatments approved by the FDA since 2014.4
    Centers for Disease Control and Prevention.

Almirall Digital Transformation Strategy Analysis Report 2023: Accelerators, Incubators, and Other Innovation Programs

Retrieved on: 
Thursday, January 11, 2024
Cloud, NTT Data, Dermatology, Patient, AI, The Rainbow Children, Tirbanibulin, Psoriasis, Onychomycosis, Therapy, Acne, NTT, Atopic dermatitis

DUBLIN, Jan. 10, 2024 /PRNewswire/ -- The "Almirall - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 10, 2024 /PRNewswire/ -- The "Almirall - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering.
  • This report provides insights into Almirall's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.
  • Almirall is leveraging several emerging technologies to quickly discover drugs, drive sales, streamline production, expand market presence and help patients recover quickly.
  • Almirall launched its dermatology digital health accelerator, Digital Garden, in 2020 to support startups that are focused on developing technology-based services and solutions for various dermatological diseases.

Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis

Retrieved on: 
Monday, November 13, 2023
Pharmacokinetics, Czech Republic, DSO, Onychomycosis, Safety, Patient, Dermatophyte, Culture, Week, Pharmaceutical industry

A 3-month treatment duration is considerably shorter than for other topical agents used for onychomycosis (~11 months).

Key Points: 
  • A 3-month treatment duration is considerably shorter than for other topical agents used for onychomycosis (~11 months).
  • The primary objective was an assessment of early clinical and/or mycological activity of BB2603-10 versus vehicle at Week 16, 1 month after end of treatment.
  • Secondary endpoints were assessed at the end of the trial at Week 52, 9 months after the end of the 3-month treatment period.
  • "We are excited to announce the successful completion of our Phase 2b trial, which delivered remarkable treatment outcomes following just three months of dosing.

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Retrieved on: 
Friday, October 6, 2023
Probability, OMX, Onychomycosis, Telephone, Marketing, Patient, Pharmaceutical industry, Airline

STOCKHOLM, Oct. 6, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America.

Key Points: 
  • STOCKHOLM, Oct. 6, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America.
  • The enrollment to the North American study has now been completed with 384 patients randomized at 33 sites in the U.S. and Canada.
  • Moberg Pharma cooperate with the same CRO, lead investigator and successful sites from the previous North American study.
  • "Completing the enrollment in North America well ahead of year-end is an important milestone and the result of excellent teamwork and committed investigators.

MOB-015 is recommended for approval in EU: Moberg Pharma

Retrieved on: 
Wednesday, June 28, 2023
OMX, Onychomycosis, Marketing, Telephone, API, Dermatology, Nail, Trial of the century, Bayer, Physician, Risk, OTC, Fungal infection, Safety, Pharmaceutical industry, Mobile phone, EU, Nordic, Terbinafine

National approvals are expected to follow during upcoming months and timelines may vary between countries.

Key Points: 
  • National approvals are expected to follow during upcoming months and timelines may vary between countries.
  • "We are excited about the MOB-015 program, with its cutting-edge technology and the promising 76% mycological cure rate shown in the clinical trials.
  • We will initiate launch as quickly as possible following national approval, expecting to initiate launch preparations in Sweden before the end of the year.
  • Exact choice of countries will depend on time to national approval - which may vary.

Diabetes Drug Drives Patient Demand for Fotona 4D Non Surgical Facelift Procedure

Retrieved on: 
Monday, March 20, 2023
Surgery, Medical Devices, Diabetes, Fitness & Nutrition, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Dentistry, Elasticity, Onychomycosis, Doctor of Philosophy, Melasma, Weight loss, Ageing, Gynaecology, Dermatology, Patient, Physician, Lifting, Collagen, Skin, Ligamentous laxity, Medical device, EU

Fotona US, the leader in the design and manufacture of high technology laser systems for aesthetics and dentistry since 1964, has noted a significant demand for Fotona 4D® Non Surgical Facelift procedures to rebuild collagen and correct sagging facial skin due to the popular off label use of a diabetes drug.

Key Points: 
  • Fotona US, the leader in the design and manufacture of high technology laser systems for aesthetics and dentistry since 1964, has noted a significant demand for Fotona 4D® Non Surgical Facelift procedures to rebuild collagen and correct sagging facial skin due to the popular off label use of a diabetes drug.
  • “Diabetes drugs like semaglutide injections are in high demand for rapid weight loss.
  • “Even if you add back volume through fillers, the skin is not going to return right back to normal.
  • Dr. Viera adds, “It offers tightening and volumization without the need for fillers or toxins which only last between 6 and 10 months.

Global Onychomycosis Clinical Trial Pipeline Landscape Report 2022-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022
Infectious Diseases, Health, Clinical Trials, Pharmaceutical industry, Oil, Onychomycosis

The "Global Onychomycosis Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Onychomycosis Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides the most up-to-date information on key pipeline products within the global Onychomycosis market.
  • It covers emerging therapies for Onychomycosis in active clinical development stages including early and late stage clinical trials.
  • The report provides Onychomycosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

The Best You® Acquires Bay Street Salon and Spa

Retrieved on: 
Tuesday, October 18, 2022
Surgery, Health, Oncology, Physician, PRP, Hyperhidrosis, Skin care, Ontario Health Insurance Plan, Dermatology, Family, Fat removal procedures, TBY, Partnership, Knowledge, You Wanted the Best, You Got the Best!!, Breast augmentation, Friends, Acquisition, Onychomycosis, Pedicure, Blepharoplasty, Leadership, Platelet-rich plasma, Hair removal, Bay Street, OHIP, Mesotherapy, Acne, Ownership, Skin cancer, United Counties of Prescott and Russell, Beauty salon, General store, National Capital Region (Canada), Embrun

The Best You (TBY), a long-standing group of medical aesthetic clinics in Ontario, today announced that it has completed the acquisition of the Bay Street Salon and Spa in Embrun, Ontario (Bay Street).

Key Points: 
  • The Best You (TBY), a long-standing group of medical aesthetic clinics in Ontario, today announced that it has completed the acquisition of the Bay Street Salon and Spa in Embrun, Ontario (Bay Street).
  • The Bay Street Salon and Spa, located 20 minutes from the outskirts of Ottawa, complements TBYs current offerings.
  • Bay Street is a family-owned and operated salon and spa, offering massage therapy, hair styling services as well as laser treatments for acne, onychomycosis and wart removal, vascular treatments, laser hair removal, and CoolSculpting.
  • With the addition of Bay Street Salon and Spa to its portfolio of companies, TBY will expand its service offerings across the Greater Ottawa area and continue to provide excellent client service based on the knowledge, expertise, and leadership of the team at Bay Street.

GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress

Retrieved on: 
Tuesday, September 6, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, PAKT, Research, Professor, Rosacea, KA, Science, Frontiers of Medicine, Congress, AM, Population, IL-31, Thought, Patient, Genetics, RESEARCH, Atopic dermatitis, Sensitive, Woman, Prurigo nodularis, Adapalene, Partnership, Chairperson, Skin, Investment, Acne, Acquisition, Prurigo, Benzoyl peroxide, European Academy of Management, Nervous system, Cetaphil, Onychomycosis, Diagnosis, PM, Perkinsus marinus, Nail, Pharmaceutical industry, Cosmetics, Sculptra, Trifarotene, Methyl aminolevulinate, Ivermectin, Adapalene/benzoyl peroxide, Venereology, Galderma, Dermatology

Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.

Key Points: 
  • Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.
  • As the pure-play dermatology leader, Galdermas significant presence at EADV reaffirms its commitment to delivering a truly innovative, science-based portfolio of premium cutting-edge brands and services.
  • Two symposia and eight scientific posters will examine the disease burden, the role of IL-31 in these inflammatory skin conditions and treatments under development.
  • EADV congress to exchange information, share insights and
    GLOBAL HEAD OF RESEARCH & DEVELOPMENT, GALDERMA
    Below is a full list of activities taking place.

Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)

Retrieved on: 
Friday, August 19, 2022
Department of Medicine – University of Pamplona, Risk, Onychomycosis, NIH, GLOBE, Drug resistance, Toxicity, Microbiology, Clemson University, Erectile dysfunction, National Institute, Infection, Pain, National Institute of Allergy and Infectious Diseases, Quality of life, Therapy, Twitter, Program, Acne, Atomic mass, Atopic dermatitis, Wound healing, Hepatotoxicity, SBIR, Albert Einstein College of Medicine, Medicine, Nitric oxide, Pharmaceutical industry, Management

GREENVILLE, SC, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $600,000 Small Business Innovation Research (SBIR) grant to generate a final formulation of Zylö’s proprietary nitric oxide-releasing topical drug candidate optimized for the treatment of onychomycosis. The grant is sponsored by the National Institute of Allergy and Infectious Diseases, a division of the NIH.

Key Points: 
  • The grant is sponsored by the National Institute of Allergy and Infectious Diseases, a division of the NIH.
  • Onychomycosis is an extremely common and difficult-to-treat fungal nail infection that causes nail disfigurement, pain, associated infections, and psychosocial effects that negatively impact quality of life.
  • Our novel nitric oxide-releasing product promises to increase nail penetration, thereby enhancing efficacy, but without the side effects typically experienced with systemic drugs.
  • Notably, the Z-pod technology can also be adapted to provide sustained topical delivery of nitric oxide for multiple therapeutic indications.